Corcept Therapeutics Inc (CORT)
28.97
-2.54
(-8.06%)
USD |
NASDAQ |
Jun 14, 16:00
29.01
+0.04
(+0.14%)
After-Hours: 20:00
Corcept Therapeutics Accounts Receivable (Quarterly): 61.52M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 61.52M |
December 31, 2023 | 41.12M |
September 30, 2023 | 34.63M |
June 30, 2023 | 32.55M |
March 31, 2023 | 32.56M |
December 31, 2022 | 31.06M |
September 30, 2022 | 29.41M |
June 30, 2022 | 28.16M |
March 31, 2022 | 27.18M |
December 31, 2021 | 27.62M |
September 30, 2021 | 26.51M |
June 30, 2021 | 27.62M |
March 31, 2021 | 22.20M |
December 31, 2020 | 26.20M |
September 30, 2020 | 21.96M |
June 30, 2020 | 22.72M |
March 31, 2020 | 26.68M |
December 31, 2019 | 19.93M |
September 30, 2019 | 22.40M |
June 30, 2019 | 19.77M |
March 31, 2019 | 19.22M |
December 31, 2018 | 17.59M |
September 30, 2018 | 19.36M |
June 30, 2018 | 28.70M |
March 31, 2018 | 17.26M |
Date | Value |
---|---|
December 31, 2017 | 15.30M |
September 30, 2017 | 11.87M |
June 30, 2017 | 9.504M |
March 31, 2017 | 9.214M |
December 31, 2016 | 9.86M |
September 30, 2016 | 8.236M |
June 30, 2016 | 9.301M |
March 31, 2016 | 6.752M |
December 31, 2015 | 6.221M |
September 30, 2015 | 5.945M |
June 30, 2015 | 4.951M |
March 31, 2015 | 4.301M |
December 31, 2014 | 3.334M |
September 30, 2014 | 2.746M |
June 30, 2014 | 2.225M |
March 31, 2014 | 1.922M |
December 31, 2013 | 1.428M |
September 30, 2013 | 1.019M |
June 30, 2013 | 0.855M |
March 31, 2013 | 1.143M |
December 31, 2012 | 0.557M |
September 30, 2012 | 0.354M |
June 30, 2012 | 0.355M |
March 31, 2012 | |
December 31, 2011 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
19.77M
Minimum
Jun 2019
61.52M
Maximum
Mar 2024
29.09M
Average
27.40M
Median
Accounts Receivable (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 60.49M |
Regeneron Pharmaceuticals Inc | 5.222B |
United Therapeutics Corp | 307.30M |
Ligand Pharmaceuticals Inc | 28.44M |
Warby Parker Inc | 1.167M |